TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9391919
Drug: Alcohol (0.62
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcohol (0.62 g/kg for men, 0.54 g/kg for women)
Study: 7349932
Drug: Individual advice
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individual advice twice a year and health education campaign in intervention factories
Study: 31821220
Drug: High-dose group
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose group (HDG): three 90-minute yoga classes and four 30-minute homework sessions per week for 12 weeks.
Study: 31821220
Drug: Low-dose group
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose group (LDG): two 90-minute yoga classes and three 30-minute homework sessions per week for 12 weeks.
Study: 28946736
Drug: Lamivudine (LAM)
Normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lamivudine (LAM) 100 mg/day
Study: 25897158
Drug: Nivolumab 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab 3 mg/kg intravenously once every 2 weeks for up to 96 weeks
Study: 25897158
Drug: Nivolumab 1,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab 1, 3, or 10 mg/kg intravenously once every 2 weeks for up to 96 weeks
Study: 21873705
Drug: Colchicine (1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colchicine (1.0 to 2.0 mg on the first day followed by 0.5 to 1.0 mg/d for 6 months)
Study: 19688320
Drug: Yinzhihuang Oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yinzhihuang Oral Liquid (YOL), 5 mL each time, twice daily
Study: 15474732
Drug: Transgenic corn
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transgenic corn expressing 1 mg of LT-B, fed in three doses of 2.1 g each.
Study: 11528274
Drug: Volatile oil
Normalized name: Volatile oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Volatile oil administered by gargling for 14 consecutive nights
Study: 27338807
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered for 14 consecutive nights
Study: 8805169
Drug: Gentamicin sulfate
Normalized name: Gentamicin Sulfate
DrugBank: Gentamicin (DB00798)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gentamicin sulfate (5 mg/kg daily) for > 10 days
Study: 8805169
Drug: Gentamicin sulfate
Normalized name: Gentamicin Sulfate
DrugBank: Gentamicin (DB00798)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gentamicin sulfate (5 mg/kg daily) for <= 7 days
Study: 6236095
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Ipratropium bromide and Fenoterol (Ip/Fen)
Study: 28433267
Drug: 20 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 μg vitamin D3
Study: 28433267
Drug: 10 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 μg calcifediol
Study: 28433267
Drug: 15 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 μg calcifediol
Study: 28433267
Drug: Calcifediol (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcifediol (10 and 15 μg)
Study: 25078385
Drug: Intravenous lignocaine
Normalized name: lidocaine hydrochloride Injectable Solution [Sure-Amp Lignocaine hydrochloride]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous lignocaine
Study: 27507582
Drug: All groups
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All groups (TAP, intravenous lignocaine, placebo)
Study: 25618125
Drug: High-frequency ultrasound
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High-frequency ultrasound (HFU) therapy
Study: 25618125
Drug: MIST ultrasound
Approvals — FDA: no, EMA: no, PMDA: no
Description: MIST ultrasound therapy
Study: 25618125
Drug: Ultrasound therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound therapy (HFU and MIST combined)
Study: 25618125
Drug: All groups
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All groups (HFU, MIST, and Standard treatment)
Study: 21262931
Drug: 20 per
Normalized name: evolocumab 420 per 3.5 ML Cartridge
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 per cent carbamide peroxide (CP) at-home bleaching agent, bonded 24 hours after bleaching (n = 40)
Study: 21262931
Drug: 20 per
Normalized name: evolocumab 420 per 3.5 ML Cartridge
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 per cent carbamide peroxide (CP) at-home bleaching agent, bonded 14 days after bleaching (n = 40)
Study: 17686443
Drug: Enzastaurin (novel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enzastaurin (novel targeted therapy, monotherapy)
Study: 17686443
Drug: Gemcitabine and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine and pemetrexed (new drugs)
Study: 17686443
Drug: Pharmacogenomics (tailored
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacogenomics (tailored therapy)
Study: 16335170
Drug: Early loading
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early loading group (20 implants); mean change in ISQ: -0.08 +/- 0.77; mean bone loss: 0.69 +/- 0.15 mm.
Study: 16335170
Drug: Unloaded group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unloaded group (21 implants); mean change in ISQ: 1.33 +/- 1.65; mean bone loss: 0.53 +/- 0.18 mm.
Study: 2160358
Drug: Long-acting propranolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long-acting propranolol 60 mg once a day for 12 weeks
Study: 2160358
Drug: Atenolol 50
Normalized name: atenolol 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol 50 mg once a day for 12 weeks
Study: 6113920
Drug: Tiotidine 25
Normalized name: Histidine
DrugBank: Histidine (DB00117)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tiotidine 25 mg
Study: 6113920
Drug: Tiotidine 50
Normalized name: Histidine
DrugBank: Histidine (DB00117)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tiotidine 50 mg
Study: 6113920
Drug: Tiotidine 100
Normalized name: Histidine
DrugBank: Histidine (DB00117)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tiotidine 100 mg
Study: 6113920
Drug: Tiotidine 150
Normalized name: Histidine
DrugBank: Histidine (DB00117)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tiotidine 150 mg
Study: 24704942
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy and endobronchial photodynamic therapy (PDT) with photosensitizer agent chlorine E6 and 662nm laser light before each of the three courses of chemotherapy.
Study: 24704942
Drug: Chemotherapy alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy alone (No-PDT arm).
Study: 24704942
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy and endobronchial PDT (PDT arm).
Study: 22791944
Drug: Epidural combined
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural combined general anesthesia (G + E)
Study: 15385354
Drug: Neostigmine 0.07
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neostigmine 0.07 mg/kg administered on reappearance of the first tactile TOF response (Group I)
Study: 15385354
Drug: Neostigmine 0.07
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neostigmine 0.07 mg/kg administered on reappearance of the second tactile TOF response (Group II)
Study: 15385354
Drug: Neostigmine 0.07
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neostigmine 0.07 mg/kg administered on reappearance of the third tactile TOF response (Group III)
Study: 15385354
Drug: Neostigmine 0.07
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neostigmine 0.07 mg/kg administered on reappearance of the fourth tactile TOF response (Group IV)
Study: 15385354
Drug: Neostigmine 0.07
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neostigmine 0.07 mg/kg administered on reappearance of the first tactile TOF response (Group I) during sevoflurane anesthesia
Study: 15385354
Drug: Neostigmine 0.07
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neostigmine 0.07 mg/kg administered on reappearance of the second tactile TOF response (Group II) during sevoflurane anesthesia
Study: 15385354
Drug: Neostigmine 0.07
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neostigmine 0.07 mg/kg administered on reappearance of the third tactile TOF response (Group III) during sevoflurane anesthesia
Study: 15385354
Drug: Neostigmine 0.07
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neostigmine 0.07 mg/kg administered on reappearance of the fourth tactile TOF response (Group IV) during sevoflurane anesthesia
Study: 11477585
Drug: Photodynamic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photodynamic therapy (PDT) using meta-tetra(hydroxyphenyl)chlorin (m-THPC) at a dose of 0.10 mg/kg bodyweight, irradiated 48 hours after drug application at a light dose of 5 J/cm².
Study: 11477585
Drug: Photodynamic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photodynamic therapy (PDT) using meta-tetra(hydroxyphenyl)chlorin (m-THPC) at a dose of 0.15 mg/kg bodyweight, illuminated 96 hours after photosensitization at a light dose of 10 J/cm².
Study: 11477585
Drug: Photodynamic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photodynamic therapy (PDT) using m-THPC.
Study: 9748876
Drug: Sequential maintenance
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential maintenance therapy (interferon alpha-2b for 3 months followed by dexamethasone)
Study: 9748876
Drug: High-dose chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose chemotherapy with melphalan (200 mg/m2)
Study: 6840159
Drug: Nifedipine 60
Normalized name: nifedipine 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine 60 mg
Study: 7317899
Drug: Nifedipine 90
Normalized name: nifedipine 90 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine 90 mg
Study: 31119583
Drug: Diet 2
Normalized name: gluc-msm-vit C-FA-mang-diet 29 125 mg-37.5 mg-25 mg-500 mcg-1.25 mg ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diet 2 (10 g kg−1 CDXOS)
Study: 31119583
Drug: Diet 3
Normalized name: Phendiet 35 MG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diet 3 (108 CFU g−1 L. plantarum CR1T5)
Study: 31119583
Drug: Diet 4
Normalized name: CIDER VINEGAR DIET FORMULA CAP/TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diet 4 (10 g kg−1 CDXOS + 108 CFU g−1 L. plantarum CR1T5)
Study: 8181024
Drug: Loop diuretic
Normalized name: Loop diuretic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loop diuretic
Study: 20151804
Drug: Subantimicrobial dose
Normalized name: GAUZE,ANTIMICROBIAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subantimicrobial dose doxycycline (SDD; 20 mg two times a day)
Study: 17531899
Drug: Treatment of
Normalized name: DRUGS FOR TREATMENT OF LEPRA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment of gestational diabetes mellitus (GDM)
Study: 16109560
Drug: Epi-CH (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epi-CH (10 mg Epi-CH injected around the primary tumor or biopsy excision 72 h before operation)
Study: 16109560
Drug: Control (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (10 mg epirubicin solution injected in the same region)
Study: 2572037
Drug: Broxaterol (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Broxaterol (400 micrograms by metered dose inhaler)
Study: 2572037
Drug: Broxaterol (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Broxaterol (0.5 mg by oral route)
Study: 2572037
Drug: Broxaterol (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Broxaterol (0.25 mg as nebulizer solution)
Study: 2572037
Drug: Broxaterol (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Broxaterol (oral and aerosol administration)
Study: 27595680
Drug: Apixaban (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apixaban (5 mg BID, with a possible reduction to 2.5 mg BID based on certain criteria; single starting dose of 10 mg or 5 mg if down-titrated)
Study: 27595680
Drug: Heparin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin plus warfarin
Study: 18608712
Drug: Isotretinoin (Iso)
Normalized name: Isotretinoin
DrugBank: Isotretinoin (DB00982)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isotretinoin (Iso) therapy for cystic acne for 45 days
Study: 18608712
Drug: Isotretinoin (Iso)
Normalized name: Isotretinoin
DrugBank: Isotretinoin (DB00982)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isotretinoin (Iso) therapy for cystic acne
Study: 12381942
Drug: High-dose calcium
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose calcium acetate (1,521 mg calcium/day)
Study: 12381942
Drug: Low-dose calcium
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose calcium acetate (507 mg calcium/day)
Study: 7781936
Drug: Antibiotic group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic group (500 mg amoxicillin q.i.d. and 500 mg tinidazole t.i.d. for 1 week)
Study: 7781936
Drug: Maintenance group
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance group (40 mg famotidine for 6 weeks followed by 20 mg famotidine at bedtime for 6 months)
Study: 29700480
Drug: Antibiotic group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic group
Study: 7781936
Drug: Antibiotic group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic group (H. pylori negative)
Study: 2195108
Drug: Insulin 3
Normalized name: Pen Needle Insulin 33 gauge 4mm
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin 3 U/h and glucagon 200 micrograms/h in 5% dextrose with 1% human albumin solution (HAS)
Study: 1959860
Drug: Insulin and
Normalized name: Isophane insulin and porcine regular insulin only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin and glucagon therapy
Study: 44117
Drug: tween‐ether‐split‐vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: tween‐ether‐split‐vaccine
Study: 44117
Drug: subunit‐vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: subunit‐vaccine
Study: 29100778
Drug: Treatment with
Normalized name: Campho-Phenique Cold Sore Treatment with Drying Action
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment with tuberculosis regimen
Study: 25892434
Drug: Medical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical treatment with loperamide and stool-bulking agents (2 months)
Study: 25892434
Drug: Combination treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination treatment (biofeedback + medical treatment)
Study: 19920269
Drug: Behavioral intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Behavioral intervention (bimonthly tailored, nurse-administered telephone intervention targeting hypertension-related behaviors)
Study: 19920269
Drug: Home BP
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Home BP monitoring (3 times weekly)
Study: 11923755
Drug: Injection therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection therapy with epinephrine‐polidocanol (1%)
Study: 11923755
Drug: Injection combined
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection combined with hemoclip
Study: 9874432
Drug: Ranitidine (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine (3 x 50 mg intravenously)
Study: 9874432
Drug: Pirenzepine (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pirenzepine (3 x 10 mg intravenously)
Study: 7711365
Drug: Treatment for
Normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment for chronic low-back pain
Study: 2560684
Drug: Glucagon (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucagon (1 mg s.c.)
Study: 2560684
Drug: Insulin (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin (0.2 U/kg i.v., ITT)
Study: 1000228
Drug: Radiant heater
Normalized name: norethindrone
DrugBank: Norethisterone (DB00717)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Radiant heater group (babies < 1500 g)
Study: 1000228
Drug: Radiant heater
Normalized name: norethindrone
DrugBank: Norethisterone (DB00717)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Radiant heater group (babies < 1000 g)
Study: 1000228
Drug: Incubator group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Incubator group (babies < 1000 g)
Study: 31511286
Drug: Short interval
Normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short interval (<3 years) between menarche and first sexual intercourse (FSI) or start of oral contraceptive (OC) use
Study: 28608926
Drug: Flibanserin 100
Normalized name: flibanserin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flibanserin 100 mg plus ethanol 0.4 g/kg
Study: 28608926
Drug: Flibanserin 100
Normalized name: flibanserin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flibanserin 100 mg plus ethanol 0.8 g/kg
Study: 22248038
Drug: Flibanserin 100
Normalized name: flibanserin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flibanserin 100 mg
Study: 28608926
Drug: Flibanserin 100
Normalized name: flibanserin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flibanserin 100 mg plus ethanol
Study: 26392753
Drug: Sibutramine (daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sibutramine (daily 12.55 mg)
Study: 21649532
Drug: Fermented milk
Normalized name: MILK
DrugBank: Cow milk (DB10543)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fermented milk product containing Ile-Pro-Pro and Val-Pro-Pro (25 mg peptides and 2 g plant sterols)
Study: 17129925
Drug: Pharmacological treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacological treatment (cyclobenzaprine)
Study: 17129925
Drug: Combined pharmacological
Normalized name: COPD pharmacologic substance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined pharmacological and cognitive-behavioral treatment
Study: 14715848
Drug: Hormone replacement
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormone replacement therapy (1 mg/d 17beta‐estradiol combined with norethisterone acetate)
Study: 11692292
Drug: Rifaximin (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifaximin (400 mg twice per day)
Study: 11692292
Drug: Ciprofloxacin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin (500 mg twice per day)
Study: 3110804
Drug: 3 g
Normalized name: Molds 3 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 g L-carnitine daily for 3 weeks
Study: 3110804
Drug: 4 g
Normalized name: CTX4 Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 g L-carnitine single oral dose
Study: 29729237
Drug: Melatonin (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin (3 mg nightly)
Study: 28760798
Drug: Elastomeric infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Elastomeric infusion pump (Baxter Infusor)
Study: 28760798
Drug: Electronic infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Electronic infusion pump (ambIT Continuous)
Study: 22946487
Drug: Metyrapone (750
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metyrapone (750 mg) with MDMA (75 mg)
Study: 8144852
Drug: Metyrapone (750
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metyrapone (750 mg)
Study: 15750189
Drug: 600-mg clopidogrel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600-mg clopidogrel loading dose
Study: 15750189
Drug: 300-mg clopidogrel
Normalized name: clopidogrel 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300-mg clopidogrel loading dose
Study: 18400718
Drug: n-3 fatty
Normalized name: n-3 fatty acids
DrugBank: Omega-3 fatty acids (DB11133)
Approvals — FDA: no, EMA: no, PMDA: no
Description: n-3 fatty acid eicosapentaenoic acid (EPA) capsules (1.5 g/d) for 6 months
Study: 18400718
Drug: No supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: No supplement (controls)
Study: 17409863
Drug: Weekly paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Weekly paclitaxel (100 mg/m for 3 of 4 weeks) and carboplatin (AUC = 6 mg/ml/min once every 4 weeks)
Study: 17409863
Drug: Weekly paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Weekly paclitaxel or observation as maintenance therapy after four cycles of chemotherapy
Study: 10776684
Drug: Mud packs
Normalized name: aminophylline / ephedrine hydrochloride / guaifenesin / phenobarbital Oral Tablet [Mudrane GG]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mud packs and sulfur baths in addition to daily exposure to sun ultraviolet rays and regular bathing at the Dead Sea (Group 1)
Study: 10776684
Drug: Daily exposure
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily exposure to sun ultraviolet rays and regular bathing at the Dead Sea (Group 2)
Study: 8737630
Drug: Oxerutins (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxerutins (2 x 500 mg daily)
Study: 1568584
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg MK-329
Study: 31822925
Drug: Inhalation of
Normalized name: Ocean brand of sodium chloride Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation of vaporized synthetic 5‐methoxy‐N,N‐dimethyltryptamine
Study: 21189766
Drug: Prop‐based oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prop‐based oral health and nutrition intervention program (8‐10 minute duration)
Study: 15955217
Drug: Terlipressin 2
Normalized name: Terlipressin
DrugBank: Terlipressin (DB02638)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terlipressin 2 mg after somatostatin 250 microg/h
Study: 8679357
Drug: 0.5% lignocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% lignocaine 3 mg kg‐1
Study: 2049321
Drug: Overall treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall treatment (RT + MVPP)
Study: 6344698
Drug: Innovar, 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Innovar, 0.1 ml/kg, intravenously
Study: 6344698
Drug: Morphine, 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine, 0.5 mg/kg, intravenously
Study: 19155896
Drug: 17 alpha‐hydroxyprogesterone
Approvals — FDA: no, EMA: no, PMDA: no
Description: 17 alpha‐hydroxyprogesterone caproate (250 mg, weekly intramuscular injections starting at 16-20 weeks until delivery or 35 weeks)
Study: 19155896
Drug: Placebo (matching
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (matching injections, same schedule as intervention)